Clinical Trials Logo

Follicular Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to Follicular Non-Hodgkin's Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03568929 Completed - Clinical trials for Follicular Non-Hodgkin's Lymphoma Refractory

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

ZEUS
Start date: May 25, 2018
Phase:
Study type: Observational

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

NCT ID: NCT02063685 Completed - Clinical trials for Follicular Non-Hodgkin's Lymphoma

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Start date: July 2012
Phase: Phase 3
Study type: Interventional

Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS). Based on the results of recently completed randomized studies the standard treatment for patients with FL should consist of an initial therapy with R-CHOP combination followed by two-year maintenance with R. Although results of randomized trials confirmed that this approach results in an improved patients' outcome and made a step forward in the management of patients with FL, one important question that can be raised is if this approach is really needed for all patients with FL or if some of them could benefit from a reduced intensity treatment achieving the same results in terms of outcome and survival . This question is of particular interest for newly diagnosed patients for whom maintenance does not affect OS. More recent data demonstrated that the outcome of patients with FL can be further predicted by evaluating the quality of response to therapy studying minimal residual disease (MRD). This project addresses the objective of evaluating if combining clinical response assessed on FDG-PET scan and molecular response measured through MRD detection could permit to single out groups of patients at different risk of progression and to consequently modulate maintenance therapies, with the aim to provide clinicians a more rational use of the available diagnostic and therapeutic resources.

NCT ID: NCT01701232 Completed - Clinical trials for Splenic Marginal Zone Lymphoma

Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma

Start date: September 2011
Phase: Phase 3
Study type: Interventional

This international multi-center, randomized, controlled, open-label study investigated the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (INN: rituximab, CJSC Biocad) versus MabThera® (INN: rituximab, F. Hoffmann La Roche, Ltd.) both administered as a monotherapy of patients with indolent non-Hodgkin's lymphoma. Patients were randomized to receive 375 mg/m² BCD-020 as intravenous infusion once a week for 4 weeks or MabThera® at the same regimen.